Form 4: Aytu BioPharma Executive Greg Pyszczymuka Reports Stock Transactions
SEC Form 4 Filing
Greg Pyszczymuka, Chief Commercial Officer of Aytu BioPharma, reports the vesting of restricted stock units and subsequent ownership of common shares.
Summary
- On March 31, 2024, Greg Pyszczymuka, the Chief Commercial Officer of Aytu BioPharma, had restricted stock units (RSUs) vest, which converted into 208 common shares.
- Following this transaction, Pyszczymuka directly owns 22,768 common shares.
- The RSUs were granted on March 31, 2022, and vest quarterly, starting March 31, 2023, and ending March 31, 2025.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock transactions, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and is a standard practice for publicly traded companies.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects a small increase in the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 03/31/2022 | Date the Restricted Stock Units (RSUs) were granted. |
| 03/31/2023 | Start date for quarterly vesting of RSUs. |
| 03/31/2024 | Date of the reported transaction where RSUs vested and converted to common shares. |
| 03/31/2025 | End date for quarterly vesting of RSUs. |
| 04/01/2024 | Date of the report filing. |
Keywords
Aytu BioPharma, Greg Pyszczymuka, Chief Commercial Officer, Form 4, Restricted Stock Units, RSUs, Common Shares, Beneficial Ownership, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.